Tissue Therapies Limited is an Australia-based biotechnology company. The Company�s is principally engaged in the research, development and commercialization of the Company�s international intellectual property in wound healing and tissue regeneration. The Company is commercializing VitroGro ECM, is a new treatment for hard to heal wounds that is used in conjunction with standard care, including moist wound dressing and compression. On January 23, 2012, Tissue Therapies Europe Limited a wholly owned subsidiary was set up to provide administration support to Tissue Therapies Limited (Parent Entity). The Company's customers are located predominantly in Australia.